Figures
Abstract
The GapC of Streptococcus dysgalactiae (S. dysgalactiae) is a highly conserved surface protein that can induce protective humoral immune response in animals. However, B-cell epitopes on the S. dysgalactiae GapC have not been well identified. In this study, a monoclonal antibody (mAb5B7) against the GapC1-150 protein was prepared. After passive transfer, mAb5B7 could partially protect mice against S. dysgalactiae infection. Eleven positive phage clones recognized by mAb5B7 were identified by screening phage-displayed random 12-peptide library, most of which matched the consensus motif DTTQGRFD. The motif sequence exactly matches amino acids 48-55 of the S. dysgalactiae GapC protein. In addition, the motif 48DTTQGRFD55 shows high homology among various streptococcus species. Site-directed mutagenic analysis further confirmed that residues D48, T50, Q51, G52 and F54 formed the core motif of 48DTTQGRFD55. This motif was the minimal determinant of the B-cell epitope recognized by the mAb5B7. As expected, epitope-peptide evoked protective immune response against S. dysgalactiae infection in immunized mice. Taken together, this identified conserved B-cell epitope within S. dysgalactiae GapC could provide very valuable insights for vaccine design against S. dysgalactiae infection.
Citation: Zhang L, Zhang H, Fan Z, Zhou X, Yu L, Sun H, et al. (2015) Identification of a Conserved Linear B-Cell Epitope of Streptococcus dysgalactiae GapC Protein by Screening Phage-Displayed Random Peptide Library. PLoS ONE 10(6): e0131221. https://doi.org/10.1371/journal.pone.0131221
Editor: Mitchell Ho, National Cancer Institute, NIH, UNITED STATES
Received: January 6, 2015; Accepted: May 30, 2015; Published: June 29, 2015
Copyright: © 2015 Zhang et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited
Data Availability: All relevant data are within the paper.
Funding: This work was supported by National “Twelfth Five-Year” Plan for Science & Technology Support (Grant Nos. 2012BAD12B03 and Nos. 2012BA12B05), National Natural Science Foundation of China (NSFC, Grant Nos. 31072120) and Science and Technology Project for Heilongjiang Agricultural Reclamation Administration (HNK11A-08-01-04). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing interests: The authors have declared that no competing interests exist.
Introduction
As one of the most important pathogens causing mastitis, the Streptococcus dysgalactiae (S. dysgalactiae) is intimately associated with intramammary infection in the dairy cow [1]. This pathogen is ubiquitous in the dairy environment and can survive for long periods only within the mammary gland [2]. The S. dysgalactiae expresses various intracellular, extracellular or cell surface proteins, which specifically interacts with host proteins. These interactions are assumed to play important roles in eliciting host immune reactivity [3–5].
Nowadays, whole organism [6], capsular carbohydrate [7], or recombinant proteins [5, 8–11] have been developed as potential vaccines. Especially, several surface proteins have been used as recombinant vaccine components, and their partial protection effects against the streptococcus infection have been achieved [3, 8, 12]. One of these surface proteins is the GapC protein, which was first identified in Group A streptococci (GAS). It is the streptococcal surface dehydrogenase (SDH) [5, 13]. SHS possesses activity of the Glyceraldehyde 3-phosphate dehydrogenase (GAPDH). This key enzyme in the glycolysis cycle of prokaryotic and eukaryotic cells reversibly catalyzes the conversion of glyceraldehyde 3-phosphate to 1, 3 bi-phosphoglycerate [14–16]. GAPDH is also a stimulatory protein that induces the proliferation and differentiation of B cells by inducing IL-10 production [17]. The GapC in different S. dysgalactiae species shares considerable homology at the DNA and amino acid levels [10], suggesting that GapC protein might be a good immunodominant antigen. The GapC protein functions as an immunodominant protein and is responsible for eliciting antibodies against S. dysgalactiae [18]. It is well known that antigen elicits immune responses mainly through its epitopes, such as B-cell epitopes. B-cell epitopes are defined as regions on the surface of the native antigen that are recognized by binding to B-cell receptors or specific antibodies [19]. Up to now, the B-cell epitopes on S. dysgalactiae GapC protein and its core sequence have not been well characterized.
Our previous study suggested that the fragment of 1 to 150 amino acids located at the N-terminus of S. dysgalactiae GapC protein could induce same immune response as the full-length GapC protein [18]. Thus in this study, the truncated GapC protein, which we named GapC1-150, was used as the immunodominant fragment. For the sake of increasing solubility of recombinant protein, the GapC1-150 was firstly expressed as a His-TrxA fusion protein. And this fusion protein was successfully purified by Ni-NTA purification system [18]. Then the neutralizing monoclonal antibody 5B7 (mAb5B7) against GapC1-150 protein of the S. dysgalactiae was generated and characterized. The precise B-cell epitope 48DTTQGRFD55 located in the N-terminus of the GapC protein was mapped through screening a phage-displayed random 12-mer peptide library. Its core motif D48T50Q51G52F54 was further identified using site-directed mutagenic analysis. These findings will aid in the further study of GapC epitope-vaccines against S. dysgalactiae.
Materials and Methods
Animals, ethics statement and production of anti-GapC mouse serum
BALB/c mice (SPF, 4–6 weeks, 18–22 g) were provided by Experimental Animal Center, Harbin Veterinary Research Institute of the Chinese Academy of Agricultural Sciences. The criteria used to determine when the animals should be humanely sacrificed includes weight loss, inappetence, weakness or inability to obtain feed or water, signs of severe organ system dysfunction, non-responsive to treatment, serve infection. Care of laboratory animals and animal experimentation were performed in accordance with animal ethics guidelines and approved by the Animal Ethics Committee of HeiLongJiang BaYi Agricultural University. The anti-GapC mouse serum was prepared in our lab, and was identified using indirect enzyme-linked immunosorbent assay (ELISA). BALB/c mice were immunized subcutaneously with 50 μg of GapC emulsified with ISA50 V2 (SEPPIC, France), followed by three boosts with the same dose at 2-week intervals. Twenty one days after the final boost, the BALB/c mice were anesthetized, humanely sacrificed and blood. The anti-GapC mouse serum was isolated from coagulated blood, and the concentration of anti-GapC immunoglobulins in this serum was determined about 100 μg/ml according to our previous study [8]. The 96-well microtitre plates were coated overnight at 4°C with S. dysgalactiae GapC, and blocked with 200 μl of PBST for 1 h at 37°C. A total of 100 μl of anti-GapC mouse serum was added, and plates were incubated for 2 h at 20°C. After washing, HRP-conjugated goat anti-mouse IgG was added, and plates were incubated for 1 h at room temperature. Plates were washed, and optical density (OD) value of each well was detected at 450 nm at room temperature.
Plasmid, cell lines and bacterial strains
To construct full-length and truncated (1-150aa) GapC of S. dysgalactiae, DNA fragment was cloned into pET-32a(+) plasmid resulting in the corresponding His-TrxA fusion protein. All of Streptococcus uberis (S. uberis), Streptococcus agalactiae (S. agalactiae) and Staphylococcus aureus (S. aureus) gapC genes were cloned into pET-30a(+) plasmid resulting in the His fusion proteins, respectively. The myeloma cell line SP2/0 was maintained in Dulbecco’s Modified Eagle’s Medium supplemented with 10% fetal calf serum (HyClone, USA) and 1% penicillin-streptomycin. Strains of S. dysgalactiae LS0312 (GenBank accession number: 30348860), S. agalactiae LS0310 (GenBank accession number: 21666598), S. uberis SD0306 (GenBank accession number: 2166660) were stored in our laboratory.
Expression and purification of recombinant proteins
Recombinant protein was expressed in E. coli strain BL21 (DE3). After the competent cells harboring the recombinant plasmid were cultivated to an A600 of 0.6 to 0.8 in LB medium at 37°C, 0.8 mM isopropyl-β-D-1-thiogalactopyranoside (IPTG) was added to the medium to induce recombinant protein expression for 3 h. Then the cells were harvested and resuspended in phosphate-buffered saline (PBS, pH7.4). The cells were disrupted by ultrasonication, and the supernatant containing soluble recombinant protein was collected. The protein with 6 × His tag was purified with Ni-NTA purification system (Merck, Germany) according to the manufacturer’s instruction. The expressed recombinant protein and its purity were analyzed by SDS-PAGE and Western blot.
Preparation and purification of mAb
Monoclonal antibodies (mAbs) against the recombinant GapC1-150 were produced using a standard procedure [20, 21]. Briefly, 4–6 weeks old BALB/c female mice were immunized by subcutaneous injection with 100 μg of the purified recombinant GapC1-150 emulsified with an equal volume of Freund’s complete adjuvant, then followed by two injections at 2-week intervals with the protein emulsified incomplete adjuvant [22]. Three days later, the mice were intraperitoneally injected with 50 μg of the antigen alone. The immunized BALB/c mice were sacrificed by cervical dislocation, and the splenic cells were harvested and fused with the SP2/0 mouse myeloma cells. The fused cells were cultured and selected in 1640 medium (HAT medium and HT medium) [23]. The mAb-producing hybridoma was cloned by limiting dilution of the cells three times. Mice were primed with a 0.5 ml adjuvant and then injected with 1–3 × 106 hybridoma cells by intraperitoneal injection. The mAbs were purified from the mice ascetic fluid using caprylic acid/ammonium sulfate precipitation (CA-AS) and the Nab Protein G Spin Purification Kit (Thermo, USA).
Characterization of mAb5B7
The mAb5B7 titer of culture supernatant or the ascites fluid was determined by indirect ELISA. Briefly, a 96-well plate was coated with 5 μg/ml of purified recombinant GapC1-150 at 4°C overnight and blocked with 5% skimmed milk dissolved in PBS at 37°C for 1 h to prevent non-specific protein binding. Then, 100 μl of supernatant of mAb-producing hybridoma culture or the ascetic fluid was added to wells and incubated at 37°C for 1 h. After washing three times with PBST, HRP-conjugated goat anti-mouse IgG (Sigma-Aldrich) or SBA Clonotyping System/HRP (Southern Biotechnology Associates Inc., USA) was incubated for 1 h at 37°C. Estimation of the enzymatic activity was carried out with TMB as the substrate. The reaction was stopped with 2 M H2SO4 and the optical density (OD) value of each well was read at 450 nm using a microplate reader (BioRad 550).
The isotype of mAb5B7 was determined using a Mouse Monoclonal Antibody Isotyping Kit (Promega, USA). The mAb specificity for binding recombinant GapC1-150 was detected by Western-blot using mAb5B7 as the primary antibody as described above. Reactivity of mAb5B7 with the whole cells of S. dysgalactiae, S. agalactiae and S. uberis were respectively determined by indirect ELISA with a 96 well-plate coated with inactivated whole bacteria.
Passive immunization with mAb5B7 in mouse
Passive immunization of mAb5B7 against S. dysgalactiae infection was performed in the following method: four-weeks-old female BALB/c mice were passively immunized intravenously with 200 μg of purified mAb5B7. Control mice were immunized with same volume of SP2/0, respectively (n = 10). Twenty-four hours later, the mice were intraperitoneally challenged with 5 × 107 CFU/mouse of S. dysgalactiae. Survival was monitored at daily intervals for 7 days after the challenge.
Screening a random phage-displayed peptide library
The Ph.D.-12 Phage Display Peptide Library (NEB, Beverly, MA, USA) containing random combination of 12-mer peptides was screened with mAb5B7 according to the manufacturer’s instruction and previous study [22]. The 96-well plate was coated with 10 μg/ml mAb5B7 (100 μl/well) at 4°C for 12 h. The well was then washed with TBST for 10 times, filled with 400 μl of blocking buffer and incubated at 4°C for 1 h. The 10 μl phage (1.5 × 1011) in 100 μl TBST was incubated and slightly shaking with the well-bound mAb at 20°C for 1 h. After TBST washing, the bound phages were then eluted with 100 μl elution buffer from the well. After neutralization with 15 μl of Tris-HCl, 1 μl phage solution was treated for dilution with LB medium and the titer of the phages was determined. Then the remaining elute was amplified by infecting 20 ml of 1:100 dilution of culture of E. coli ER2738. The culture was incubated with vigorous vibrating at 37°C for 4 h. At last, the supernatant was colleted and precipitated with PEG/NaCl. The phage yield rate was counted by the following calculation: recovery = (eluted phage/input phage) × 100%. After three rounds of repeat biopanning, positive phage clones were randomly selected and their reactivity to the mAb5B7 was verified by sandwich ELISA. The single strand phage DNAs of the positive phage clones verified by sandwich ELISA were extracted and sequenced with primer 5’-TGAGCGGATAACAATTTCAC-3’ as described by the manufacturer’s instructions (New England Biolabs, UK). The phage peptide sequences were deduced from the DNA sequences and aligned with the GapC sequence using the MEGALIGN programme in DNAStar software.
Precise defining of the epitope with mutagenic analysis
To determine the crucial amino acids of the epitope, each amino acid residue of the epitope was substituted with alanine. A series of complementary oligonucleotides coding for the wild-type and mutated versions of the epitope motif were synthesized by GENEWIZ and were cloned into pGEX-6p-1 vector (Table 1), resulting in a series of recombinant plasmids. The recombinant plasmids were induced to express recombinant GST-fusion proteins. The mAb5B7 was used as primary antibody, and reactivities of various GST fusions with mAb5B7 were detected using Western blot. At the same time, we have mutated each residue of the epitope to alanine in the full-length GapC, and the binding affinities with mAb5B7 were determined in accordance with the mutation of epitope peptide.
SDS-PAGE and Western blot
Approximately equivalent amount of recombinant fusion protein was subjected to 12% sodium dodecyl sulfate-polyacrylamide gel electrophoresis (12% SDS-PAGE). The gel was either stained with commassie blue staining solution or electrophoretically transferred onto nitrocellulose membranes (BioRad, Mississauga, ON, Canada). PBS with 5% (w/v) skimmed milk was used to block the membranes. Following wash with PBST (0.5% Tween-20) three times, the membrane was incubated with primary antibody at a corresponding dilution in PBS for 1 h at room temperature. After wash three times with PBST, 100 μl HRP-conjugated goat anti-mouse IgG (Sigma, USA) was added at a corresponding dilution in PBS and incubated at 37°C for 1 h. The reaction was developed by 3, 3’-diaminobenzidine (DAB).
Vaccine trial with the epitope peptide
To determine the protective immunity induced by the epitope peptide, each group including 10 BALB/c mice was immunized subcutaneously with 50 μg of GapC1-150 or GST-fusion epitope peptide emulsified with ISA50 V2, followed by two boosts with the same dose at 2-week intervals. Mice, immunized with the same amount of GST and PBS, were used as controls. Ten days after the final boost, all mice were intraperitoneally (i.p.) challenged with a lethal dose of S. dysgalactiae (5 × 107 CFU/mouse). Animals were monitored on a daily basis and humanely euthanized when they exhibited defined humane endpoints.
Results
Expression and purification of recombinant protein
The recombinant GapC1-150 was expressed as a His-TrxA fusion protein and purified by Ni-NTA purification system (Merck). The molecular weight of the recombinant GapC1-150 was approximate 35KD examined by 12% SDS-PAGE, in accordance with the molecular weight of the predicted protein. The recombinant GapC1-150 protein was further confirmed by Western blot using mouse anti-His monoclonal antibody and mouse GapC anti-serum, respectively (Fig 1). The results showed that the recombinant GapC1-150 was correctly expressed and well purified.
The fusion protein was confirmed with Western Blot using anti-His antibody and anti-GapC serum, respectively.
Characterization of mAb5B7
Three cell lines of hybridoma that secreted anti-GapC1-150 mAbs were established by the hybridoma technique. One of the cell lines, referred to as mAb5B7, could stably secrete anti-GapC antibody at high titer for more than 10 passages. Antibody titers of culture supernatant and ascites fluid were 1: 64000 and 1: 1.12 × 105, respectively. The mAb5B7 against the recombinant GapC1-150 was successfully purified from mouse ascites (Fig 2A). The class of the mAb5B7 was determined to be IgG1 and κ chain (55KD, 26KD) (Fig 2B). The purified GapC1-150 could be probed with mAb5B7, but not with control normal ascites, confirming that GapC1-150 containing specific epitope recognized by mAb5B7 (Fig 2C).
(A) The purified mAb5B7 was determined by SDS-PAGE. (B) The class of the mAb5B7 was determined to be IgG1 and κ chain using mouse mAb isotyping kit. (C) GapC1-150 recognized by mAb5B7 was detected using Western Blot. (D) The reactivity of mAb5B7 with the recombinant GapC of S. dysgalactiae, S. uberis, S. agalactiae and S. aureus was determined by Western blot. (E) The reactivity of mAb5B7 with the whole bacteria of inactivated S. dysgalactiae, S. agalactiae and S. uberis was confirmed by indirect ELISA (* P < 0.05; ** P < 0.01). (F) Passive immunization of mAb5B7 against S. dysgalactiae infection was performed and its protective effect was determined.
The sequence homology of GapC1-150 protein among S. dysgalactiae, S. agalactiae and S. uberis is more than 93%. However, the S. aureus GapC1-150 displays a low degree of 63% sequence homology. Western blot analysis showed that mAb5B7 recognized recombinant GapC proteins of S. dysgalactiae, S. agalactiae and S. uberis, but did not recognize recombinant GapC protein of S. aureus (Fig 2D). The reactivity of mAb5B7 with the whole cells of the three streptococcus species was determined by indirect ELISA. The results showed that the mAb5B7 could significantly react with the whole cells of S. dysgalactiae, S. agalactiae and S. uberis (Fig 2E). These results implied that the epitope of three streptococcus species GapC1-150 was conserved and exposed on bacterial surface, which could be readily recognized by mAb5B7.
In order to investigate the protective effects of mAb5B7, passive immunization against S. dysgalactiae infection was performed. The results showed that all mice in control group were dead within 2 days. However, the mice immunized with mAb5B7 or GapC anti-serum survived for much longer time after S. dysgalactiae challenge (Fig 2F). These results implied that the mAb5B7 had a certain extent of immune protection against S. dysgalactiae infection, even not stronger than the GapC anti-serum.
Epitopes prediction
To further determine the epitopes of GapC and decrease the number of laboratory experiments, bioinformatics was used to predict the epitopes. The secondary structure and the surface properties of the GapC1-150 were analyzed (Fig 3). Based on these results, the most probable epitope regions recognized by mAb5B7 were within the N-terminus amino acids 35–37, 48–53, 78–82 or 102–107 of GapC1-150 protein.
Phage-displayed epitope biopanned by mAb5B7
After three successive rounds of biopanning, the screened phages bound to the mAb5B7 were well enriched and yield of positive phage clones increased obviously (Table 2). Twenty-five clones selected by mAb5B7 were analyzed by sandwich ELISA, and eleven clones among them showed specific reactivity to mAb5B7 (Fig 4). The single-strand phage DNAs extracted from the 11 ELISA-confirmed positive clones was sequenced and the amino acid sequences were deduced. The amino acid sequences of the 11 clones showed a consensus motif DTTQGRFD (Table 3). The motif DTTQGRFD is located in amino acids 48–55 of the N-terminus of the S. dysgalactiae GapC1-150 protein. We propose that the motif°DTTQGRFD55 is an epitope of the S. dysgalactiae GapC1-150, which consistent with our prediction.
Wild-type M13 phage was used as a negative control. BSA-coated wells were used to exclude cross-activity. The E. coli ER2738 culture supernatant was blank control.
Precise defining of the epitope
To verify the epitope precisely, DNA fragments coding the motif 48DTTQGRFD55 and a series of mutated motifs AYDTTqgrfd, KADTTqgrfd, KYATTqgrfd, KYDATqgrfd, KYDTAqgrfd, KYDTTAgrfd, KYDTTqArfd, KYDTTqgAfd, KYDTTqgrAd, KYDTTqgrfA were expressed as GST-fusion protein, respectively. Western blot results showed that D48A, T50A, Q51A, G52A and F54A mutations completely destroyed the reactivity of the epitope with mAb5B7. However, the mutants R53A showed slightly reduced reactivity of the epitope with mAb5B7 (Fig 5A). In order to further determine the contribution of amino acids in the epitope peptide, we mutated each residue of the epitope to alanine in the full-length GapC, and determined their binding affinity with mAb5B7. The results showed that D48A, T50A, Q51A, G52A and F54A mutations abolished the reactivity of the epitope with mAb5B7 (Fig 5B). These results confirm that the motif 48DTTQGRFD55 is an authentic epitope in the GapC protein of S. dysgalactiae and the motif represents the minimal reactivity unit of the linear epitope recognized by mAb5B7.
(A) The reactivity of various recombinant GST-fusion proteins with mAb5B7 was confirmed using Western blot. The mutant amino acids are underlined. (B) The reactivity of various mutant full-length GapC proteins with mAb5B7 was confirmed using Western blot. The mutant amino acids are highlighted with number.
Alignment of the epitope sequence on GapC from different species
To analyze whether the linear epitope recognized by mAb5B7 is conserved, the epitope sequences of 7 Streptococcus species and 9 other microbial species are aligned. The results show that all amino acids in the motif are identical among all 7 Streptococcus species, suggesting that the motif 48DTTQGRFD55 represents a highly conserved epitope on the GapC protein of all Streptococcus species. However, the epitope motif of Streptococcus is different from the motif in other microbial species (Table 4).
Protective immunity elicited by epitope peptide
To evaluate the immune responses of the epitope 48DTTQGRFD55, the purified GapC1-150 protein, GST-epitope peptide, GST and PBS-immunized mice were challenged (i.p) with S. dysgalactiae on day 10 after the last immunization. We first tested the antibody production in the immunized mice using indirect ELISA method, and the results indicated that antibody titer of the GapC1-150 protein and GST-epitope peptide was 1: 64000 and 1: 32000, respectively. Recombinant GapC1-150 had the lowest mortality of all groups, with a 70% survival rate. GST-epitope peptide-immunized mice had the second lowest mortality with 40% survival rate, although immune protection of epitope was not stronger than the GapC1-150. In contrast, GST protein and PBS couldn’t evoke protective immune responses, and no mice in two groups could survive via lethal challenge (Fig 6A). These results suggest that B-cell epitope elicits strong immune protection against S. dysgalactiae infection, and they also promote us to further investigate the difference in binding affinity of antibody mAb5B7 to the full-length GapC protein, GapC1-150 fragment and the GapC epitope fragment. The binding affinity was determined with indirect ELISA, and the results indicated that binding affinity of full-length GapC and GapC1-150 fragment was stronger than the GapC epitope fragment at concentration of 0.1–1.0 μg. Although the relative affinity on full-length GapC was slightly higher than GapC1-150 and GapC epitope fragments, there was not significant difference among these three different fragments (Fig 6B). These results are similar with the immune protection in animals dosed with the different fragments, suggesting that these fragments might evoker intensive immune response.
(A) Protective rate of immunized and control mice following challenge with S. dysgalactiae GapC. Immunized and control mice were challenged i.p. with S. dysgalactiae bacterial suspension (equivalent to 5 × 107 CFU) on day 10 after the last immunization. Mice were monitored every day for day 60, and the data of day 14 were represented. (B) The difference in binding affinity of antibody mAb5B7 to the full-length GapC protein, GapC1-150 fragment and the GapC epitope fragment at concentration of 0.1–1.0 μg was determined with indirect ELISA.
Discussion
Elucidating the essential feature of a pathogen’s epitope recognized by antibodies can provide important information about the molecular mechanisms of immune [24]. Considerable evidence has been accumulated regarding the role of GapC protein in adhesion of S. dysgalactiae to host cells and pathogenesis, which is responsible for inducing protective immune response [13, 25]. Mapping the B-cell epitope of GapC is one of the crucial steps for the development of epitope-based vaccine against S. dysgalactiae. In this study, through screening phage-displayed random peptide 12-library with mAb5B7, we characterized a linear B-cell epitope in the GapC protein of S. dysgalactiae. The epitope matched to the consensus motif 48DTTQGRFD55, and site-directed mutagenic analysis confirmed that this core motif is the minimal requirement unit for the linearized epitope. Both mouse hyperimmune antisera and mAb5B7 against GapC showed strong reactivity with the identified B-cell epitope. More importantly, strong protective immunity was elicited by the epitope peptide.
Besides an important protein involving in glycolysis and pathogenesis, the GapC can also induce effective protection against streptococcus infection [8]. The functional and immunobiological characteristics of GapC make it a good candidate for the development of a prophylactic vaccine against streptococcus infection [5]. Through our previous experimental research, we confirmed that recombinant GapC could partially provide protection against streptococcus infection [18]. It is reported that monoclonal antibody technology are widely used to map B-cell epitopes [22, 26]. Subsequently, we seek to produce monoclonal antibody against GapC using hybridoma technique. One of cell clones, mAb5B7 with stable secretion of high titer antibody of IgG1 and κ, was obtained. The purified mAb5B7 could recognize the GapC proteins of S. dysgalactiae, S. agalactiae and S. uberis, but neither the GapC of S. aureus (Fig 2D) nor other recombinant proteins of S. aureus (data not shown), suggesting the reactivity between mAb5B7 and GapC was extremely specificity. The mAb5B7 can react with the whole cells of the three streptococcus species, indicating that the epitope recognized by the mAb5B7 is exposed on the bacterial surfaces. Furthermore, mAb5B7 possessed partial protection against S. dysgalactiae infection after passive transfer of the mAb5B7 into naive mice. These results showed that monoclonal antibody of GapC was successfully generated.
Bioinformatics method is an efficient way to predict epitope. Therefore, we used two online software programs (http://tools.immuneepitope.org/main/ and http://www.cbs.dtu.dk/services/BepiPred/) to predict the B-cell epitopes of the truncated GapC1-150 protein. The online prediction showed that the 30-50aa fragment of the GapC received the highest scores (Fig 3) and this fragment was determined as the continuous-epitope fragments. The phage displayed random peptide library is a vigorous tool for mapping B-cell epitopes recognized by monoclonal antibody [27]. In order to further verify the correctness of the above epitope prediction, we identified immunodominant B-cell epitopes within the truncated GapC1-150 by screening the Ph.D.-12 Phage Display Peptide Library using the mAb5B7. Through analysis of reactivity of the mAb5B7 to the positive phage clones and alignment of the positive phage sequences, a linear B-cell epitope recognized by mAb5B7 was defined as DTTQGRFD. This peptide sequence is identical to 48DTTQGRFD55, which is located in the N-terminus with GapC protein of S. dysgalactiae (Table 3). Furthermore, substitutions of the individual amino acids within the 48DTTQGRFD55 showed that residues D48A, T50A, Q51A, G52A and F54A mutations completely destroyed the reactivity with the mAb5B7. Thus, the peptide 48DTTQGRFD55 is determined to be the minimal unit of the epitope with the maximal binding activity to mAb5B7.
Lastly, sequences alignment of B-cell epitope was performed between S. dysgalactiae and other species in the genus streptococcus. The results indicate that streptococcus displays 100% sequence homology among various species, but the other bacteria possessing GapC protein display a low degree of sequence homology (Table 4). These results are consistent with the experimental data that the mAb5B7 react with the GapC proteins of S. dysgalactiae, S. uberis, S. agalactiae, but not react with GapC of S. aureus. Moreover, immunization with epitope peptide of GapC could significantly evoke protection against challenge of S. dysgalactiae. Therefore, it may be an effective antigenic epitope for further study of epitope-based vaccines against streptococcus infections.
Conclusions
Taken together, we have identified a highly conserved linear B-cell epitope in the N-terminus of S. dysgalactiae GapC protein. These data may provide an explanation of the GapC-induced protection against three streptococcus species and highlight the possibility of developing the epitope-based vaccine against the streptococcus.
Acknowledgments
We are grateful to Prof. Paul Chu (Guest Professor of Institute of Microbiology, Chinese Academy of Sciences) and Dr. Zhenhua Yang (University of Alabama at Birmingham) for critical reading of the manuscript.
Author Contributions
Conceived and designed the experiments: LZ HZ ZF YC. Performed the experiments: LZ XZ LY HS ZW. Analyzed the data: YY BS JM. Contributed reagents/materials/analysis tools: CT XW. Wrote the paper: HZ ZZ YC.
References
- 1. Barkema HW, Schukken YH, Lam TJ, Beiboer ML, Benedictus G, Brand A. Management practices associated with the incidence rate of clinical mastitis. J Dairy Sci 1999; 82: 1643–1654. pmid:10480089
- 2. Calvinho LF, Almeida RA, Oliver SP. Potential virulence factors of Streptococcus dysgalactiae associated with bovine mastitis. Vet Microbiol. 1998; 61: 93–110. pmid:9646469
- 3. Song XM, Perez-Casal J, Bolton A, Potter AA. Surface-expressed mig protein protects Streptococcus dysgalactiae against phagocytosis by bovine neutrophils. Infect Immun. 2001; 69: 6030–6037. pmid:11553540
- 4. Song XM, Perez-Casal J, Fontaine MC, Potter AA. Bovine immunoglobulin A (IgA)-binding activities of the surface-expressed Mig protein of Streptococcus dysgalactiae. Microbiol-Sgm. 2002; 148: 2055–2064. pmid:12101294
- 5. Bolton A, Song XM, Willson P, Fontaine MC, Potter AA, Perez-Casal J. Use of the surface proteins GapC and Mig of Streptococcus dysgalactiae as potential protective antigens against bovine mastitis. Can J Microbiol. 2004; 50: 423–432. pmid:15284888
- 6. Mackie DP, Pollock DA, Meneely DJ, Logan EF. Clinical features of consecutive intramammary infections with Streptococcus agalactiae in vaccinated and non-vaccinated heifers. Vet Rec. 1983; 112: 472–476. pmid:6346659
- 7. Almeida RA, Oliver SP. Antiphagocytic Effect of the Capsule of Streptococcus-Uberis. J Vet Med B. 1993; 40: 707–714.
- 8. Fontaine MC, Perez-Casal J, Song XM, Shelford J, Willson PJ, Potter AA. Immunisation of dairy cattle with recombinant Streptococcus uberis GapC or a chimeric CAMP antigen confers protection against heterologous bacterial challenge. Vaccine. 2002; 20: 2278–2286. pmid:12009283
- 9. Lindahl G, Stalhammar-Carlemalm M, Areschoug T. Surface proteins of Streptococcus agalactiae and related proteins in other bacterial pathogens. Clin Microbiol Rev. 2005; 18: 102–127. pmid:15653821
- 10. Perez-Casal J, Prysliak T, Potter AA. A GapC chimera retains the properties of the Streptococcus uberis wild-type GapC protein. Protein Expr Purif. 2004; 33: 288–296. pmid:14711517
- 11. Rainard P, Lautrou Y, Sarradin P, Poutrel B. Protein X of Streptococcus agalactiae induces opsonic antibodies in cows. J Clin Microbiol. 1991; 29: 1842–1846. pmid:1774305
- 12. Stalhammarcarlemalm M, Stenberg L, Lindahl G. Protein Rib—a Novel Group-B Streptococcal Cell-Surface Protein That Confers Protective Immunity and Is Expressed by Most Strains Causing Invasive Infections. J Exp Med. 1993; 177: 1593–1603. pmid:8496678
- 13. Pancholi V, Fischetti VA. A major surface protein on group-a Streptococci is a glyceraldehyde-3-phosphate-dehydrogenase with multiple binding-activity. J Exp Med. 1992; 176: 415–426. pmid:1500854
- 14. van der Merwe J, Prysliak T, Gerdts V, Perez-Casal J. Protein chimeras containing the Mycoplasma bovis GAPDH protein and bovine host-defence peptides retain the properties of the individual components. Microb Pathog. 2011; 50: 269–277. pmid:21296650
- 15. Taylor JM, Heinrichs DE. Transferrin binding in Staphylococcus aureus: involvement of a cell wall-anchored protein. Mol Microbiol. 2002; 43: 1603–1614. pmid:11952908
- 16. Pancholi V, Fischetti VA. Cell-to-cell signalling between group A streptococci and pharyngeal cells. Role of streptococcal surface dehydrogenase (SDH). Adv Exp Med Biol. 1997; 418: 499–504. pmid:9331703
- 17. Cheung AL, Fischetti VA. The role of fibrinogen in staphylococcal adherence to catheters in vitro. J Infect Dis. 1990; 161: 1177–1186. pmid:2345298
- 18.
Che C. Expression and Immunogenicity of GapC protein of S. agalactiae, S. dysgalactiae, S. uberis. M.Sc. Thesis, HeiLongJiang BaYi Agricultural University. Available: http://cdmd.cnki.com.cn/Article/CDMD-10223-2009223191.htm. Accessed 26 November 2014.
- 19. Viudes A, Perea S, Lopez-Ribot JL. Identification of continuous B-cell epitopes on the protein moiety of the 58-kiloDalton cell wall mannoprotein of Candida albicans belonging to a family of immunodominant fungal antigens. Infect Immun. 2001; 69: 2909–2919. pmid:11292706
- 20. Mazzarotto GA, Raboni SM, Stella V, Carstensen S, de Noronha L, Levis S, et al. Production and characterization of monoclonal antibodies against the recombinant nucleoprotein of Araucaria hantavirus. J Virol Methods. 2009; 162: 96–100. pmid:19654026
- 21. Kohler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature. 1975; 256: 495–497. pmid:1172191
- 22. Li Y, Ning YS, Wang YD, Luo J, Wang W, Dong WQ, et al. Production of mouse monoclonal antibodies against Helicobacter pylori Catalase and mapping the antigenic epitope by phage display library. Vaccine. 2008; 26: 1263–1269. pmid:18241959
- 23. Yu Y, Wang H, Zhao L, Zhang C, Jiang Z, Yu L. Fine mapping of a foot-and-mouth disease virus epitope recognized by serotype-independent monoclonal antibody 4B2. J Microbiol. 2011; 49: 94–101. pmid:21369985
- 24. Wei JC, Huang YZ, Zhong DK, Kang L, Ishag H, Mao X, et al. Design and evaluation of a multi-epitope peptide against Japanese encephalitis virus infection in BALB/c mice. Biochem Biophys Res Commun. 2010; 396: 787–792. pmid:20457131
- 25. Brassard J, Gottschalk M, Quessy S. Cloning and purification of the Streptococcus suis serotype 2 glyceraldehyde-3-phosphate dehydrogenase and its involvement as an adhesin. Vet Microbiol. 2004; 102: 87–94. pmid:15288930
- 26. Xue M, Shi X, Zhang J, Zhao Y, Cui H, Hu S, et al. Identification of a conserved B-cell epitope on reticuloendotheliosis virus envelope protein by screening a phage-displayed random peptide library. PLoS One. 2012; 7: e49842. pmid:23185456
- 27. Rowley MJ, O'Connor K, Wijeyewickrema L. Phage display for epitope determination: a paradigm for identifying receptor-ligand interactions. Biotechnol Annu Rev. 2004; 10: 151–188. pmid:15504706